Selpercatinib (LOXO-292) is a potent, selective RET tyrosine kinase inhibitor with antineoplastic activity. Demonstrates nanomolar potency against wild-type RET (IC50=14.0nM) and maintains activity against clinically relevant mutations V804M (IC50=24.1nM) and G810R (IC50=530.7nM).
Usually ships within 24 hours.